Inceptor Bio Enters into Collaboration with the University of Minnesota for the Development of iPSC Platform to Treat Cancer
Shots:
- Under the terms of the agreement, Inceptor Bio will receive an exclusive license for the novel iPSC platform developed in collaboration with the University of Minnesota by accelerating Inceptor Bio's cell therapies platforms for the treatment of difficult-to-treat cancers
- Inceptor Bio plans to include the newly developed iPSC platform into its proprietary K62 for CAR_M therapy which increases the phagocytic capabilities of macrophages & supports the M1 anti-tumor phenotype along with the M83 costimulatory domain
- iPSC-derived cell therapies have the potential to enable the next frontier of cell therapies & therefore will further advance Inceptor Bio’s multiple cell therapy products
Ref: PR Newswire | Image: PR Newswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
